English
简体中文
Total: £ 56.28
Published Date: 2026-03-25 | Pages: 133 | Tables: 138 | Pharma & Healthcare
The global Immunosuppressants in Cancer Therapy market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)
The North American market for Immunosuppressants in Cancer Therapy is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Immunosuppressants in Cancer Therapy is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Immunosuppressants in Cancer Therapy in Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Immunosuppressants in Cancer Therapy include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Immunosuppressants in Cancer Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Immunosuppressants in Cancer Therapy. The Immunosuppressants in Cancer Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Immunosuppressants in Cancer Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Immunosuppressants in Cancer Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
CAR-T Cell Therapy
Other
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Immunosuppressants in Cancer Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immunosuppressants in Cancer Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 CAR-T Cell Therapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Immunosuppressants in Cancer Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Prostate Cancer
1.3.5 Blood-related Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immunosuppressants in Cancer Therapy Market Perspective (2021–2032)
2.2 Global Immunosuppressants in Cancer Therapy Growth Trends by Region
2.2.1 Global Immunosuppressants in Cancer Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Immunosuppressants in Cancer Therapy Historic Market Size by Region (2021–2026)
2.2.3 Immunosuppressants in Cancer Therapy Forecasted Market Size by Region (2027–2032)
2.3 Immunosuppressants in Cancer Therapy Market Dynamics
2.3.1 Immunosuppressants in Cancer Therapy Industry Trends
2.3.2 Immunosuppressants in Cancer Therapy Market Drivers
2.3.3 Immunosuppressants in Cancer Therapy Market Challenges
2.3.4 Immunosuppressants in Cancer Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immunosuppressants in Cancer Therapy Players by Revenue
3.1.1 Global Top Immunosuppressants in Cancer Therapy Players by Revenue (2021–2026)
3.1.2 Global Immunosuppressants in Cancer Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top Immunosuppressants in Cancer Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Immunosuppressants in Cancer Therapy Revenue
3.4 Global Immunosuppressants in Cancer Therapy Market Concentration Ratio
3.4.1 Global Immunosuppressants in Cancer Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immunosuppressants in Cancer Therapy Revenue in 2025
3.5 Global Key Players of Immunosuppressants in Cancer Therapy Head Offices and Areas Served
3.6 Global Key Players of Immunosuppressants in Cancer Therapy, Products and Applications
3.7 Global Key Players of Immunosuppressants in Cancer Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Immunosuppressants in Cancer Therapy Breakdown Data by Type
4.1 Global Immunosuppressants in Cancer Therapy Historic Market Size by Type (2021–2026)
4.2 Global Immunosuppressants in Cancer Therapy Forecasted Market Size by Type (2027–2032)
5 Immunosuppressants in Cancer Therapy Breakdown Data by Application
5.1 Global Immunosuppressants in Cancer Therapy Historic Market Size by Application (2021–2026)
5.2 Global Immunosuppressants in Cancer Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Immunosuppressants in Cancer Therapy Market Size (2021–2032)
6.2 North America Immunosuppressants in Cancer Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Immunosuppressants in Cancer Therapy Market Size by Country (2021–2026)
6.4 North America Immunosuppressants in Cancer Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immunosuppressants in Cancer Therapy Market Size (2021–2032)
7.2 Europe Immunosuppressants in Cancer Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Immunosuppressants in Cancer Therapy Market Size by Country (2021–2026)
7.4 Europe Immunosuppressants in Cancer Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Immunosuppressants in Cancer Therapy Market Size (2021–2032)
8.2 Asia-Pacific Immunosuppressants in Cancer Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Immunosuppressants in Cancer Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific Immunosuppressants in Cancer Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Immunosuppressants in Cancer Therapy Market Size (2021–2032)
9.2 Latin America Immunosuppressants in Cancer Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Immunosuppressants in Cancer Therapy Market Size by Country (2021–2026)
9.4 Latin America Immunosuppressants in Cancer Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immunosuppressants in Cancer Therapy Market Size (2021–2032)
10.2 Middle East & Africa Immunosuppressants in Cancer Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Immunosuppressants in Cancer Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa Immunosuppressants in Cancer Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Immunosuppressants in Cancer Therapy Introduction
11.1.4 AbbVie Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.1.5 AbbVie Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Immunosuppressants in Cancer Therapy Introduction
11.2.4 Johnson & Johnson Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Immunosuppressants in Cancer Therapy Introduction
11.3.4 Novartis Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.3.5 Novartis Recent Development
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Details
11.4.2 Gilead Sciences Business Overview
11.4.3 Gilead Sciences Immunosuppressants in Cancer Therapy Introduction
11.4.4 Gilead Sciences Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.4.5 Gilead Sciences Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Immunosuppressants in Cancer Therapy Introduction
11.5.4 Roche Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.5.5 Roche Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Immunosuppressants in Cancer Therapy Introduction
11.6.4 Bristol-Myers Squibb Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Immunosuppressants in Cancer Therapy Introduction
11.7.4 Amgen Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Immunosuppressants in Cancer Therapy Introduction
11.8.4 AstraZeneca Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.8.5 AstraZeneca Recent Development
11.9 Merck & Co
11.9.1 Merck & Co Company Details
11.9.2 Merck & Co Business Overview
11.9.3 Merck & Co Immunosuppressants in Cancer Therapy Introduction
11.9.4 Merck & Co Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.9.5 Merck & Co Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Immunosuppressants in Cancer Therapy Introduction
11.10.4 Takeda Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.10.5 Takeda Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Details
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Immunosuppressants in Cancer Therapy Introduction
11.11.4 Merck KGaA Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.11.5 Merck KGaA Recent Development
11.12 Seagen
11.12.1 Seagen Company Details
11.12.2 Seagen Business Overview
11.12.3 Seagen Immunosuppressants in Cancer Therapy Introduction
11.12.4 Seagen Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.12.5 Seagen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Immunosuppressants in Cancer Therapy Introduction
11.13.4 Eli Lilly Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.13.5 Eli Lilly Recent Development
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Details
11.14.2 Ono Pharmaceutical Business Overview
11.14.3 Ono Pharmaceutical Immunosuppressants in Cancer Therapy Introduction
11.14.4 Ono Pharmaceutical Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.14.5 Ono Pharmaceutical Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Details
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Immunosuppressants in Cancer Therapy Introduction
11.15.4 Pfizer Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.15.5 Pfizer Recent Development
11.16 GSK
11.16.1 GSK Company Details
11.16.2 GSK Business Overview
11.16.3 GSK Immunosuppressants in Cancer Therapy Introduction
11.16.4 GSK Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.16.5 GSK Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Immunosuppressants in Cancer Therapy Introduction
11.17.4 Exelixis Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.17.5 Exelixis Recent Development
11.18 Regeneron
11.18.1 Regeneron Company Details
11.18.2 Regeneron Business Overview
11.18.3 Regeneron Immunosuppressants in Cancer Therapy Introduction
11.18.4 Regeneron Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.18.5 Regeneron Recent Development
11.19 Innovent
11.19.1 Innovent Company Details
11.19.2 Innovent Business Overview
11.19.3 Innovent Immunosuppressants in Cancer Therapy Introduction
11.19.4 Innovent Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.19.5 Innovent Recent Development
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Details
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Immunosuppressants in Cancer Therapy Introduction
11.20.4 Hengrui Medicine Revenue in Immunosuppressants in Cancer Therapy Business (2021–2026)
11.20.5 Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Immunosuppressants in Cancer Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Cytokine-Based Immunotherapy
Table 4. Key Players of CAR-T Cell Therapy
Table 5. Key Players of Other
Table 6. Global Immunosuppressants in Cancer Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Immunosuppressants in Cancer Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Immunosuppressants in Cancer Therapy Market Size by Region (US$ Million), 2021–2026
Table 9. Global Immunosuppressants in Cancer Therapy Market Share by Region (2021–2026)
Table 10. Global Immunosuppressants in Cancer Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Immunosuppressants in Cancer Therapy Market Share by Region (2027–2032)
Table 12. Immunosuppressants in Cancer Therapy Market Trends
Table 13. Immunosuppressants in Cancer Therapy Market Drivers
Table 14. Immunosuppressants in Cancer Therapy Market Challenges
Table 15. Immunosuppressants in Cancer Therapy Market Restraints
Table 16. Global Immunosuppressants in Cancer Therapy Revenue by Players (US$ Million), 2021–2026
Table 17. Global Immunosuppressants in Cancer Therapy Market Share by Players (2021–2026)
Table 18. Global Top Immunosuppressants in Cancer Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Immunosuppressants in Cancer Therapy Revenue, 2025
Table 19. Ranking of Global Top Immunosuppressants in Cancer Therapy Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Immunosuppressants in Cancer Therapy Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Immunosuppressants in Cancer Therapy, Headquarters and Area Served
Table 22. Global Key Players of Immunosuppressants in Cancer Therapy, Products and Applications
Table 23. Global Key Players of Immunosuppressants in Cancer Therapy, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Immunosuppressants in Cancer Therapy Market Size by Type (US$ Million), 2021–2026
Table 26. Global Immunosuppressants in Cancer Therapy Revenue Market Share by Type (2021–2026)
Table 27. Global Immunosuppressants in Cancer Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Immunosuppressants in Cancer Therapy Revenue Market Share by Type (2027–2032)
Table 29. Global Immunosuppressants in Cancer Therapy Market Size by Application (US$ Million), 2021–2026
Table 30. Global Immunosuppressants in Cancer Therapy Revenue Market Share by Application (2021–2026)
Table 31. Global Immunosuppressants in Cancer Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Immunosuppressants in Cancer Therapy Revenue Market Share by Application (2027–2032)
Table 33. North America Immunosuppressants in Cancer Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2021–2026
Table 35. North America Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Immunosuppressants in Cancer Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Immunosuppressants in Cancer Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Immunosuppressants in Cancer Therapy Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Immunosuppressants in Cancer Therapy Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Immunosuppressants in Cancer Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Immunosuppressants in Cancer Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Immunosuppressants in Cancer Therapy Market Size by Country (US$ Million), 2027–2032
Table 48. AbbVie Company Details
Table 49. AbbVie Business Overview
Table 50. AbbVie Immunosuppressants in Cancer Therapy Product
Table 51. AbbVie Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 52. AbbVie Recent Development
Table 53. Johnson & Johnson Company Details
Table 54. Johnson & Johnson Business Overview
Table 55. Johnson & Johnson Immunosuppressants in Cancer Therapy Product
Table 56. Johnson & Johnson Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 57. Johnson & Johnson Recent Development
Table 58. Novartis Company Details
Table 59. Novartis Business Overview
Table 60. Novartis Immunosuppressants in Cancer Therapy Product
Table 61. Novartis Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 62. Novartis Recent Development
Table 63. Gilead Sciences Company Details
Table 64. Gilead Sciences Business Overview
Table 65. Gilead Sciences Immunosuppressants in Cancer Therapy Product
Table 66. Gilead Sciences Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 67. Gilead Sciences Recent Development
Table 68. Roche Company Details
Table 69. Roche Business Overview
Table 70. Roche Immunosuppressants in Cancer Therapy Product
Table 71. Roche Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 72. Roche Recent Development
Table 73. Bristol-Myers Squibb Company Details
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Immunosuppressants in Cancer Therapy Product
Table 76. Bristol-Myers Squibb Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 77. Bristol-Myers Squibb Recent Development
Table 78. Amgen Company Details
Table 79. Amgen Business Overview
Table 80. Amgen Immunosuppressants in Cancer Therapy Product
Table 81. Amgen Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 82. Amgen Recent Development
Table 83. AstraZeneca Company Details
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Immunosuppressants in Cancer Therapy Product
Table 86. AstraZeneca Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 87. AstraZeneca Recent Development
Table 88. Merck & Co Company Details
Table 89. Merck & Co Business Overview
Table 90. Merck & Co Immunosuppressants in Cancer Therapy Product
Table 91. Merck & Co Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 92. Merck & Co Recent Development
Table 93. Takeda Company Details
Table 94. Takeda Business Overview
Table 95. Takeda Immunosuppressants in Cancer Therapy Product
Table 96. Takeda Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 97. Takeda Recent Development
Table 98. Merck KGaA Company Details
Table 99. Merck KGaA Business Overview
Table 100. Merck KGaA Immunosuppressants in Cancer Therapy Product
Table 101. Merck KGaA Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 102. Merck KGaA Recent Development
Table 103. Seagen Company Details
Table 104. Seagen Business Overview
Table 105. Seagen Immunosuppressants in Cancer Therapy Product
Table 106. Seagen Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 107. Seagen Recent Development
Table 108. Eli Lilly Company Details
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Immunosuppressants in Cancer Therapy Product
Table 111. Eli Lilly Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 112. Eli Lilly Recent Development
Table 113. Ono Pharmaceutical Company Details
Table 114. Ono Pharmaceutical Business Overview
Table 115. Ono Pharmaceutical Immunosuppressants in Cancer Therapy Product
Table 116. Ono Pharmaceutical Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 117. Ono Pharmaceutical Recent Development
Table 118. Pfizer Company Details
Table 119. Pfizer Business Overview
Table 120. Pfizer Immunosuppressants in Cancer Therapy Product
Table 121. Pfizer Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 122. Pfizer Recent Development
Table 123. GSK Company Details
Table 124. GSK Business Overview
Table 125. GSK Immunosuppressants in Cancer Therapy Product
Table 126. GSK Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 127. GSK Recent Development
Table 128. Exelixis Company Details
Table 129. Exelixis Business Overview
Table 130. Exelixis Immunosuppressants in Cancer Therapy Product
Table 131. Exelixis Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 132. Exelixis Recent Development
Table 133. Regeneron Company Details
Table 134. Regeneron Business Overview
Table 135. Regeneron Immunosuppressants in Cancer Therapy Product
Table 136. Regeneron Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 137. Regeneron Recent Development
Table 138. Innovent Company Details
Table 139. Innovent Business Overview
Table 140. Innovent Immunosuppressants in Cancer Therapy Product
Table 141. Innovent Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 142. Innovent Recent Development
Table 143. Hengrui Medicine Company Details
Table 144. Hengrui Medicine Business Overview
Table 145. Hengrui Medicine Immunosuppressants in Cancer Therapy Product
Table 146. Hengrui Medicine Revenue in Immunosuppressants in Cancer Therapy Business (US$ Million), 2021–2026
Table 147. Hengrui Medicine Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Immunosuppressants in Cancer Therapy Picture
Figure 2. Global Immunosuppressants in Cancer Therapy Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Immunosuppressants in Cancer Therapy Market Share by Type: 2025 vs 2032
Figure 4. Immune Checkpoint Inhibitors Features
Figure 5. Cytokine-Based Immunotherapy Features
Figure 6. CAR-T Cell Therapy Features
Figure 7. Other Features
Figure 8. Global Immunosuppressants in Cancer Therapy Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Immunosuppressants in Cancer Therapy Market Share by Application: 2025 vs 2032
Figure 10. Lung Cancer Case Studies
Figure 11. Breast Cancer Case Studies
Figure 12. Prostate Cancer Case Studies
Figure 13. Blood-related Cancer Case Studies
Figure 14. Other Case Studies
Figure 15. Immunosuppressants in Cancer Therapy Report Years Considered
Figure 16. Global Immunosuppressants in Cancer Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 17. Global Immunosuppressants in Cancer Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Immunosuppressants in Cancer Therapy Market Share by Region: 2025 vs 2032
Figure 19. Global Immunosuppressants in Cancer Therapy Market Share by Players in 2025
Figure 20. Global Immunosuppressants in Cancer Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Immunosuppressants in Cancer Therapy Revenue in 2025
Figure 22. North America Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. North America Immunosuppressants in Cancer Therapy Market Share by Country (2021–2032)
Figure 24. United States Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Canada Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Europe Immunosuppressants in Cancer Therapy Market Share by Country (2021–2032)
Figure 28. Germany Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. France Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. U.K. Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Italy Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Russia Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Ireland Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Asia-Pacific Immunosuppressants in Cancer Therapy Market Share by Region (2021–2032)
Figure 36. China Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Japan Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. South Korea Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Southeast Asia Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. India Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Australia & New Zealand Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Latin America Immunosuppressants in Cancer Therapy Market Share by Country (2021–2032)
Figure 44. Mexico Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Brazil Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Middle East & Africa Immunosuppressants in Cancer Therapy Market Share by Country (2021–2032)
Figure 48. Israel Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Saudi Arabia Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. UAE Immunosuppressants in Cancer Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. AbbVie Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 52. Johnson & Johnson Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 53. Novartis Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 54. Gilead Sciences Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 55. Roche Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 57. Amgen Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 58. AstraZeneca Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 59. Merck & Co Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 60. Takeda Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 61. Merck KGaA Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 62. Seagen Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 63. Eli Lilly Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 64. Ono Pharmaceutical Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 65. Pfizer Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 66. GSK Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 67. Exelixis Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 68. Regeneron Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 69. Innovent Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 70. Hengrui Medicine Revenue Growth Rate in Immunosuppressants in Cancer Therapy Business (2021–2026)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
